Can we pause 177Lu-PSMA-617 therapy after a good response?
Treatments studied
Part of Cancer, Kidney & urinary clinical trials.
This trial tests whether it's safe to pause 177Lu-PSMA-617 therapy in men whose prostate cancer has responded very well to it. Doctors want to see if taking a break from treatment can reduce side effects without letting the cancer come back.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have metastatic castrate-resistant prostate cancer (cancer that has spread and is no longer responding to hormone therapy).
- Your cancer is PSMA-positive (shows up on a special PET scan).
- You are receiving or scheduled to receive 177Lu-PSMA-617 therapy at Mayo Clinic Rochester.
- You have had a near-complete response (most cancer gone) on a scan after 2 to 5 cycles of treatment.
- Your blood counts and kidney/liver function are good enough for the treatment.
- You do not have any other active cancer or serious uncontrolled illness.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of two treatments for men with prostate cancer that has spread to a small number of sites: a radioactive injection (177Lu-PSMA-617) that targets cancer cells, plus hormone-blocking medication. The goal is to control the cancer and delay progression.
This trial tests if a second round of a targeted radiation therapy (177Lu-PSMA-617) can help men whose prostate cancer has returned after a successful first treatment. It is for men whose cancer has stopped responding to hormone therapy and chemotherapy, and whose PSA levels have risen again after a prior good response to this drug.
This trial is testing if a higher first dose of Lu-177-PSMA-617, a targeted radiation therapy, can improve outcomes for men with metastatic castration-resistant prostate cancer that shows up on a PSMA PET scan. The goal is to see if it is safe and effective.
This trial tests two different dosing schedules of a drug called Lutetium-177 PSMA RLT, which delivers radiation directly to prostate cancer cells. It is for men with advanced prostate cancer that has stopped responding to hormone therapy and has spread, who have not yet had chemotherapy for this stage of the disease.
This trial tests a higher dose of a radioactive drug (177Lu-PSMA-617) for men whose prostate cancer has spread and does not produce much of a protein called PSMA on scans. The goal is to see if a stronger dose can work better than the standard dose.
This trial uses a blood test to measure tumor DNA and see if men with advanced prostate cancer can safely stop treatment with a drug called 177Lu-PSMA-617 earlier than usual, or switch to chemotherapy. It may help reduce side effects while still controlling the cancer.
Hear when a new Castration-Resistant Prostate Carcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.